Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
BAY 1129980 / 16044An open-label phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumours known to express C4.4aHirte, Dr HalOpenNCT02134197
CPI-444-001A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersHotte, Dr Sebastien OpenNCT02655822
GO29313A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSHirte, Dr HalOpenNCT02219724
IND.214A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid TumoursHotte, Dr Sebastien OpenNCT02285816
IND.226A PHASE IB STUDY OF DURVALUMAB (MEDI4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH ADVANCED INCURABLE SOLID MALIGNANCIES RECEIVING STANDARD CHEMOTHERAPY REGIMENSJuergens, Dr RosalynOpenNCT02537418
IND.228A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare TumoursHirte, Dr HalOpenNCT02879162
MDV3800-01 (TRIO031)A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal ImpairmentHirte, Dr HalOpenNCT02997163
MDV3800-13A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With TalazoparibHirte, Dr HalOpenNCT02921919
BAY 80-6946 / 16270An open-label, non-randomized, Phase I study to evaluate the effect of itraconazole on the pharmacokinetics of a single intravenous dose of copanlisib in patients with advanced solid tumorsHirte, Dr HalOn holdNCT02253420
Download PDF